• 希格生科 completed the first close of a Series A+ financing of several hundred million, led by 国寿股权.
• Tiantu Capital led its angel round in 2021, then invested again in the angel-plus round that October.
• The investor also participated in the company’s Series A financing early this year.
• The Shenzhen-based drug developer uses organoid models and AI to develop treatments for cancer, heart disease and kidney disease.
• Proceeds will advance core oncology drugs toward pivotal trials, support new heart and kidney disease pipelines, and improve its drug discovery platform.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shenzhen Tiantu Capital Management Center (LP) published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.